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Methylprednisolone enhances the efficacy of ondansetron in acute and
delayed cisplatin-induced emesis over at least three cycles
B. Chevallierl, M. Marty2, J.-M. Paillarse3 and the Ondansetron Study Group*
'Centre Anti-Cancereux Henri Becquerel, 76038 Rouen, France; 2H6pital Saint-Louis, Paris, France; 3Departement Medical,
Laboratoires Glaxo, Paris, France.
Summary This double-blind multicentre study has been carried out in order to confirm the improvement of
ondansetron's antiemetic efficacy when combined with a corticosteroid and to determine whether this increased
efficacy is maintained over three chemotherapy courses. One hundred and two patients receiving their first
course of cisplatin (50-120 mg m2)-containing chemotherapy were randomised to receive one of the two
following treatments: 8 mg OND i.v. injection and 120 mg MPD i.v. injection before chemotherapy, followed
8-12 h later by an 8 mg OND tablet and a 16 mg MPD tablet (oral treatment administered twice daily for
3-5 days); or 8 mg OND plus placebo i.v. injection before chemotherapy, followed by 8-12 h later by an
8 mg OND tablet and placebo p.o. (oral treatment administered twice daily for 3-5 days). The number of
emetic episodes (EEs = vomits + retches) and the grade of nausea were recorded. Of the 101 patients studied
(efficacy analysis), complete or major control (0-2 EEs) was experienced in 90.4% of patients in the first 24 h
in the OND/MPD group compared with 71.4% of patients in the OND group during the first course. This
difference in favour of OND/MPD was noted over the three courses and is statistically significant. In the
control of delayed emesis (worst day between days 2 and 6) there is a trend in favour of the OND/MDP group
during the first course [56.2% vs 43.2% for complete response (no emetic episodes)] which was statistically
significant on courses 2 and 3. The global antiemetic control over the course was always in favour of
OND/MPD, which leads to a better efficacy maintained over the three courses. Both treatments were well
tolerated. The results of this study confirm the increased antimetic efficacy of ondansetron and methylpred-
nisolone in combination in cisplatin-induced acute and delayed emesis which led to a better maintained efficacy
over three repeated chemotherapy courses.
In many cancer types, cisplatin is one of the most effective
cytotoxic drugs currently available, but it is also one of the
most emetogenic (Hellenbrecht & Saller, 1986).
Ondansetron is an antagonist of the 5-HT3 serotonin
receptors; its antiemetic efficacy is superior to that of high-
dose metoclopramide in the prevention of cisplatin-induced
nausea and vomiting (De Mulder et al., 1990; Hainsworth et
al., 1991; Marty & d'Allens, 1990).
In a recent study, it was demonstrated that a single 8 mg
ondansetron i.v. injection is as effective as a single 32 mg i.v.
injection in the prevention of acute emetic episodes in
patients receiving their first course of chemotherapy
(Seynaeve et al., 1992). Similarly, it was demonstrated in
another recent study that the antiemetic efficacy of ondan-
setron administered at a dose of 8 mg every 12 h in the
prevention of the prolonged emesis seen after non-cisplatin
chemotherapy is similar to the efficacy of a dose of 8 mg
administered every 8 h (Dicato et al., 1992). Corticosteroids
in combination with metoclopramide (Kris et al., 1985) or
ondansetron (Roila et al., 1991) can increase the antiemetic
efficacy of these compounds. This synergetic activity with
ondansetron was studied closely in the control of acute
emesis during a first course of chemotherapy (Roila et al.,
1991; Smyth et al., 1991).
The aim of this study was to confirm the improvement in
the antiemetic activity of ondansetron in combination with a
corticosteroid on the day of the cisplatin administration, and
on subsequent days; moreover, the combination was studied
over a further two successive courses.
Patients and methods
Patient selection
Patients > 18 years receiving their first cisplatin-containing
(50-120 mg m-2) chemotherapy, administered on the first
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day of the study, with a maximum duration of infusion up to
4 h were admitted to the study. The scheduled treatment was
to include at least three chemotherapy courses, each with a
time interval of 2-5 weeks. Cisplatin was administered at the
dosage and mode as specified for the first course.
Patients must have had no vomiting or retching requiring
an antiemetic treatment during the 24 h prior to the start of
the study. Moreover, patients who received other active
antiemetic drugs because of episodes of vomiting which were
unrelated to chemotherapy could not be included in this
study.
The protocol was approved by the Ethics Committee of St
Louis Hospital, Paris. This study was conducted in accor-
dance with good clinical practice and the Declaration of
Helsinki, each patient having given written informed con-
sent.
Methodology and calculation ofthe requirednumber of
subjects
This was a multicentre, randomised, parallel-group, double-
blind study.
The required number of patients was based on a complete
response (no emetic episode) rate being experienced by 55%
of patients on the first day of the first chemotherapy course
with ondansetron alone, and in 80% of patients when com-
bined with methylprednisolone.
Therefore, the minimum number of evaluable patients
required was 46 per group, with a risk of a= 5% and a
power of 80% (one-sided test), i.e. a total of 92 patients.
Antiemetic treatments studied
The patients were randomised to one of the two following
groups:
1. Ondansetron plus methylprednisolone group (OND/
MPD). The antiemetic treatment included one 8 mg
ondansetron and 120mg methylprednisolone i.v. injec-
tion, 30 min before the start of chemotherapy. Eight to
12 h later, the oral treatment began, combining one 8 mg
ondansetron tablet with one 16 mg methylprednisolone
capsule. The treatment was continued morning and even-
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ing over the following 3-5 days; the duration of treat-
ment was left to the investigator.
2. Ondansetron group (OND). The antiemetic treatment
included one 8 mg ondansetron and a placebo i.v. injec-
tion, 30 min before the start of chemotherapy. Eight to
12 h later, the oral treatment began, combining one 8 mg
ondansetron tablet with one placebo capsule. The treat-
ment was continued morning and evening over the fol- +
lowing 3-5 days; the duration of the treatment was left
to the investigator.
Assessment criteria
The number of emetic episodes (EEs) during the 6 days
following the start of chemotherapy, the time of onset in the
first 24 h and nausea, were recorded on a diary card. An BE E dJ was defined as any vomiting or unproductive retch, alone or
in series, but separated by a minimum time interval of 1 min.
The response to treatment was graded from complete control - =
(0 EEs), major (1-2 EEs), minor (3-5 EEs) and failure
(more than 5 EEs or rescue treatment).
The primary end-point was the antiemetic response over o
the 24h after the start of the first chemotherapy course.
Delayed emesis was scored by assessing the antiemetic res-
ponse on the 'worst' day (day 2-6). ' +
Nausea was assessed before treatment, then each day after, .t m
using a four point graded scale, corresponding to the conse-
quences of nausea on the patient's daily activity (grade of , Y C
nausea: none, mild, moderate or severe). A self-assessment of v X
nausea was also carried out by means of a visual analogue .C
scale, from 0 mm (nausea as severe as can be imagined) to 4-
100mm (absence of nausea).
These different assessment criteria were collected over the .= o
first three cisplatin-containing chemotherapy courses. E i
Adverse events were recorded during the week following
the start of chemotherapy. A causal link with the study = C
treatment was established by the investigator, and in case of E
a serious adverse event a drug surveillance enquiry was made
to assess the degree of causality with the study drug.
Statistical analysis +
All the patients were included in the efficacy analysis if they >
had complied with the protocol during the first 24 h of the
study. Treatments were compared over the first 24 h after the
start of chemotherapy, on the worst day between day 2 and
0 *
day 6 and over the whole chemotherapy course. These com- ., _
parisons were made on the four-class repartition over the E
three successive chemotherapy courses. C Z
The quantitative variables were compared using an
analysis of variance or the non-parametric Wilcoxon test. , .o0
Comparisons of the qualitative variables were carried out 0
using Fisher's sided exact test, or a chi-square test, or a C_
maximum likelihood test according to the theoretical popula- o o
tion size.
0%
Table I Study population at entry in the trial"
Ondansetron+o
Ondansetron methylprednisolone
n=49 n=52 >
Age (years) 53.8 (± 1.6) 56.7 (± 1.7)
mean (±standard deviation)
Sex ratio (M:F) 2:1 1:1
Body surface area (m2) 1.71 (±0.02) 1.68 (±0.03)
mean (±s.d.)
Alcohol consumption (%)
>1 4 units/day' 28.6 306 17.3 26. >4 units/dayb } 30.6 9.6 ) 26.9
Cisplatin dose (mgm2) on the
first chemotherapy course, 89.5 (±2) 90.1 (± 2)
mean (±standard deviation)
'There is no statistically significant difference between the two
study groups. bone alcohol unit = one glass of liqueur or one glass of
wine (12.5 cl) or one glass of beer (25 cl). CP= 0.69.
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Results
One hundred and two patients were included in this study;
one patient was not included in the efficacy analysis (pre-
existent administration of corticosteroids, not authorised in
this study).
The main characteristics of these 101 evaluable patients are
shown in Table I: 49 patients were randomised to the OND
group and 52 patients to the OND/MPD group (the first
chemotherapy course). The numbers of withdrawals were
similar in the three courses in both groups (from 49 patients
following course I to 34 in course 3 for OND and 52 patients
following course I to 39 in course 3 for OND/MPD). How-
ever, overall, eight patients from the OND group were with-
drawn from the study owing to the lack of efficacy of the
antiemetic treatment compared with three in the OND/MPD
group. All patients were included in the safety analysis.
Control ofacute emesis
Control of acute emetic episodes (Table II) The control of
acute emesis in the 24 h following the administration of
cisplatin was always better in the OND/MPD group. The
combination gave a statistically significant difference in each
of the three courses, more than 90% of patients being in
complete or major control (i.e. 0-2 EEs).
Control of nausea (Table III) A difference in favour of the
combination was observed in all three courses and reached
statistical significance for courses 2 and 3.
The patient self-assessment, carried out at 24 h using the
visual analogue scale, confirms that the antiemetic effect of
ondansetron is superior, with 80.6 mm for OND versus
88.9 mm for OND/MPD in the first course (P= 0.17),
69.7 mm versus 87.2 mm in the second course (P= 0.003)
and 72.9 mm versus 93.3 mm in the third course
(P = 0.004).
Control ofdelayed emetic episodes (Table IV)
The control of delayed emetic episodes occurring on the
worst day between day 2 and day 6 shows a trend for the
combination to be superior, resulting in an improved con-
tinuous antiemetic efficacy over the three courses of
chemotherapy. The difference was statistically significant dur-
ing the second and third courses of chemotherapy.
Global control ofemetic episodes (Table V)
The analysis of the global antiemetic response for each
chemotherapy course shows a better maintained anti-emetic
efficacy with the combination over the three courses.
Safety
The adverse events reported during the three previous
courses are presented in Table VI. Headache was the most
frequently reported adverse event. The overall number of
adverse events is smaller in the OND/MPD group; in partic-
ular, headache was less frequently reported. Septicaemia with
a favourable outcome was reported in this group. A cause
relationship with the treatment seemed doubtful as it
resolved despite the continuation of the antiemetic treatment.
No other serious adverse event linked with the treatment was
reported during the study.
Discussion
Both study treatment groups were well balanced for the main
prognostic factors (Clavel, 1991) of chemotherapy-induced
emesis (age, alcohol consumption and cisplatin dose).
Females, in whom the emetic risk is higher, were in a higher
proportion in the ondansetron/methylprednisolone group,
although the difference was not statistically significant. How-
ever, in order to take into account this difference between the
two groups for this major prognostic factor, the overall
statistical tests were adjusted for sex.
The results of this study confirm the usual rates of anti-
emetic response seen with ondansetron when administered
alone as a single 8 mg i.v. injection in patients following
high-dose cisplatin-containing chemotherapy (Marty, 1990:
Seynaeve et al., 1992): this success rate, 70% during the 24 h
following chemotherapy, was also seen in the two following
courses.
As already reported by many authors (Roila et al., 1991;
Smyth et al., 1991), the antiemetic efficacy of ondansetron in
combination with corticosteroids is enhanced in acute emesis
in patients following moderately emetogenic chemotherapies,
with 90% of patients being showing complete or major res-
ponse on the first day ofchemotherapy. The results noted for
nausea show the superiority of the combination.
Oral administration of an 8 mg tablet twice daily led to
complete or major control in two out of three patients on the
worst day; higher success rates were obtained in another
study, with less emetogenic chemotherapy (Dicato et al.,
1991) than those of the present study, which involved high
doses of cisplatin (mean dose 90 mg m-2). The methylpred-
nisolone dose administered in delayed emesis is roughly
equivalent to the dexamethasone dose used in another study
(Kris et al., 1989) which showed the advantage of using
corticosteroids in the delayed phase.
The findings with ondansetron in combination with
methylprednisolone in delayed emesis confirm the efficacy of
such a combination, even if we have to take into account the
probable impact on the delayed phase of a superior efficacy
in the first 24 h (Smyth et al., 1991). Among the patients
evaluable at each course, the efficacy is maintained over the
subsequent chemotherapeutic courses, with 67% of patients
experiencing complete response on the worst day of the third
course.
Ondansetron in combination with methylprednisolone per-
mits a better maintained antiemetic activity over the
chemotherapy courses, with 74% of patients reporting com-
plete or major response during the third mildly emetogenic
chemotherapeutic course (acute and delayed emesis). These
results confirm two previous studies one covering three
cisplatin-containing chemotherapy courses (Italian Group for
Anti-emetic Research, 1993) and the other one covering six
moderately emetogenic chemotherapeutic courses (Soukop et
al., 1992). However in these two studies corticosteroids were
given only on the first day of each course.
Table III Control of nausea over 24 h following the administration of cisplatin: results over the three courses
Grade of nausea
None
Mild
Moderate
Severe
Anti-emetic response, number of patients (%)
Course 1* Course 2** Course 3***
Ondansetron Ondansetron + M Ondansetron Ondansetron + M Ondansetron + M Ondansetron
n=49 n=52 n=40 n=42 n=35 n=39
30 (61.2) 40 (76.9) 15 (37.5) 30 (71.4) 16 (45.7) 30 (76.9)
6 (12.2) 3 (5.8) 10 (25) 6 (14.3) 7 (20) 5 (12.8)
8 (16.3) 5 (9.6) 7 (17.5) 4 (9.5) 4 (11.4) 4 (10.3)
5 (10.2) 4 (7.7) 8 (20) 2 (4.8) 8 (22.9)
*P=0.128. **P=0.001. ***P=0.001. M, methylprednisolone.0)
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Table VI Safety over the three courses
Ondansetron +
Adverse events Ondansetron methylprednisolone
Number of courses 127 133
Number of adverse events' 20 7
Constipation 4 2
Diarrhoea 3 0
Epigastralgia 2 0
Headache 10 4
Vagal discomfort 1 0
Septicaemia 0 1
aWhich in the investigator's opinion are related to the treatment.
The present study confirms the major antiemetic efficacy of
ondansetron and corticosteroids in combination already men-
tioned by various authors (Roila et al., 1991; Smith et al.,
1991; Soukop et al., 1992) and confirms its activity over three
identical chemotherapy courses. Moreover, this combination
has shown its superiority over some of the reference
antiemetic regimens: metoclopramide, dexamethasone and
diphenhydramine (Italian Group for Anti-emetic Research,
1992).
Overall, both treatments were well tolerated, with a trend
towards a lower rate of adverse events in the OND/MPD
group, in particular a decreased frequency of headache; this
trend has already been noted in other studies combining
ondansetron with corticosteroids (Marty, 1990; Roila et al.,
1991; Smith et al., 1991).
Our study clearly confirms the increased antiemetic efficacy
of ondansetron plus methylprednisolone in combination in
both acute and delayed cisplatin-induced emesis, and shows a
better maintained antiemetic efficacy over three
chemotherapy courses without undue safety problems.
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